September 23, 2019 / 5:15 AM / 24 days ago

BRIEF-Roche Presents New Data From Its Oncology Portfolio At European Oncology Congress

Sept 23 (Reuters) - Roche Holding AG:

* ROCHE TO PRESENT NEW DATA FROM ITS BROAD ONCOLOGY PORTFOLIO AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 2019 CONGRESS

* FIRST POSITIVE RESULTS FROM A PHASE III CANCER IMMUNOTHERAPY COMBINATION STUDY IN PEOPLE WITH PREVIOUSLY UNTREATED ADVANCED BLADDER CANCER

* FIRST RESULTS FROM BFAST STUDY TESTING FOUNDATION MEDICINE’S FOUNDATIONONE® LIQUID BIOPSY ASSAY TO IDENTIFY PATIENTS WHO MAY BE ELIGIBLE FOR ALECENSA® (ALECTINIB)

* FIRST RESULTS FROM POSITIVE PHASE III IMPOWER110 STUDY OF TECENTRIQ® (ATEZOLIZUMAB) MONOTHERAPY AS AN INITIAL TREATMENT FOR ADVANCED LUNG CANCER Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below